Active Ingredient History
Dexpramipexole (KNS-760704) is an orally administered drug candidate shown to selectively and significantly lower eosinophil counts in human blood and tissue. The drug is currently in clinical development for eosinophil-associated diseases by Knopp Biosciences LLC. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Amyotrophic Lateral Sclerosis (Phase 3)
Asthma (Phase 2)
Healthy Volunteers (Phase 1)
Hypereosinophilic Syndrome (Phase 2)
Renal Insufficiency (Phase 1)
Sinusitis (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue